Not a subscriber ?  Start your complimentary Premium trial now
 

ResMed Inc RMD Articles

 
News Articles: top ^

Here are the earnings season standouts and disappointments

Author: Anthony Fensom
Date: 14 Sep 2016

Amid subdued expectations, which were the biggest winners and losers? Morningstar's head of equities research, Peter Warnes, said the 2016 season "was reasonable and a little better than generally expected" under the circumstances.

Growth assets for the new financial year

Author: Anthony Fensom
Date: 12 Jul 2016

So, which asset classes might perform better in the new financial year? Small was beautiful in the year to 30 June, with the S&P/ASX 200 Index posting its first fall in four years, dropping by 4.1 per cent to finish at 5,233.

ASX stocks to watch post-Brexit

Author: Nicholas Grove
Date: 27 Jun 2016

Mike Amey, head of sterling portfolio management at PIMCO, said the shock of the vote will dominate initial market moves and will "clearly provide risks for the medium term"

CSL, Cochlear to run to $120?

Author: Nicki Bourlioufas
Date: 13 May 2016

Last year, the big question in the financial media was which company's shares would hit $100 first: CSL's (CSL) , Commonwealth Bank's (CBA) or Macquarie Group's (MQG) ? As this headline asked last May: "Will Macquarie beat Commonwealth Bank to $100?" Shortly after, this headline appeared: "Cochlear, Macquarie Bank race to the $100 share price mark."

Buying the biotech innovation boom

Author: Anthony Fensom
Date: 06 Apr 2016

Biotechnology may have suffered the slings and arrows of regulatory fortune in recent times, but there are still gains to be made by investors willing to take a longer-term punt on the "innovation boom"

4 high-growth stocks for Australia Day

Author: Christine St Anne
Date: 24 Jan 2014

With Australia Day close at hand, millions of Australians will soon be celebrating the history of this great nation

4 investment trends for 2014

Author: Christine St Anne
Date: 13 Jan 2014

1

4 top US-dollar-exposed stocks

Author: Nicholas Grove
Date: 17 Dec 2013

In Morningstar's recently published Market Outlook , head of equities research Peter Warnes says that "tailwinds are still blowing" for those Australian companies that derive the bulk of their earnings from offshore


 
Stock Quotes: top ^

ResMed Inc. (RMD)

Industry Group:
Sector:
Market Cap:$14,575 M (as of 23/06/2017 04:41 PM )
Style: Medium Growth
View Price Quote: for ResMed Inc.

Advantages of Premium Membership

Your Money Weekly Newsletter

Independent stocks newsletter has been aiding Australian investors for over 30 years.

Independent Fund Analyst Research

For the first time in Australia Morningstar Qualitative Fund Research is directly available to individual investors.

Portfolio X-Ray

Ensure your portfolio is positioned exactly how you want with Morningstar's Portfolio X-Ray. You can discover how much of a stock you really own, individually and through managed funds with Stock Intersection.

Investment Picks

Find greatly undervalued stocks to consider daily. Browse our Fund Analyst Picks to find managed funds that best suit your needs.

Access these features and more when you sign up for Premium Membership.